Merck MS Drug Misses Late-Stage Trial Target
Wall Street Journal
Merck KGaA’s shares fell around 13% after its multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials.
https://www.wsj.com/articles/merck-ms-drug-fails-to-meet-target-of-late-stage-trials-3bb8225d